IRX3 depletion promotes early cardiac commitment of hiPSC-Derived Cardiomyocytes

Agatha Ribeiro Kalthof1, Nikolas Dresch Ferreira1, Caio Mateus Silva1

  • 1Laboratorio de Genetica e Cardiologia Molecular, Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil.

Plos One
|June 16, 2026
PubMed

Insights

Suppressing IRX3 expression significantly enhances human induced pluripotent stem cell-derived cardiomyocyte (hiPSC-CM) differentiation. This leads to improved cardiomyocyte structure, function, and electrophysiology for cardiac repair applications.

Area of Science:

  • Cardiovascular Biology
  • Stem Cell Biology
  • Developmental Biology

Background:

  • Generating mature human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) is crucial for cardiac disease modeling and regenerative medicine.
  • The transcription factor Irx3 plays a role in cardiac development, but its specific function in hiPSC-CM differentiation is unclear.

Purpose of the Study:

  • To investigate the role of IRX3 in human cardiomyocyte differentiation.
  • To determine if suppressing IRX3 enhances hiPSC-CM maturation and function.

Main Methods:

  • Generated IRX3-knockout (KO) hiPSCs.
  • Differentiated hiPSCs into cardiomyocytes and analyzed differentiation efficiency.
  • Assessed cardiomyocyte structure, electrophysiology, mitochondrial function, and intercellular connectivity.

Main Results:

  • IRX3 depletion enhanced hiPSC-CM differentiation, increasing cardiomyocyte yield and expression of key markers (TNNI1, CX43).
  • IRX3-KO cardiomyocytes showed improved electrophysiological properties, mitochondrial distribution, sarcomere organization, and connectivity.
  • IRX3 suppression increased expression of cardiac transcription factors (GATA4, NKX2-5, TBX5) and cell proliferation in cardiac progenitors.

Conclusions:

  • IRX3 is a key regulator of early cardiac commitment during hiPSC-CM differentiation.
  • Suppression of IRX3 enhances the molecular and functional phenotype of hiPSC-derived cardiomyocytes.
  • Targeting IRX3 offers a potential strategy to improve hiPSC-CMs for therapeutic applications.

Related Concept Videos